Grant of Interim Extension of the Term of U.S. Patent No. 7,259,184; Vernakalant Hydrochloride, 53036 [2021-20764]
Download as PDF
<![CDATA[
53036
Federal Register / Vol. 86, No. 183 / Friday, September 24, 2021 / Notices
except for permission to market or use
the product commercially, the ‘184
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the
extended expiration date of the patent,
i.e., October 6, 2021, interim extension
of the ‘184 patent’s term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,259,184 is granted for a period of one
year from the extended expiration date
of the ‘184 patent.
www.fisheries.noaa.gov/national/
partners/marine-fisheries-advisorycommittee-meeting-materials-andsummaries by October 4, 2021.
Dated: September 21, 2021.
Jennifer L. Lukens,
Federal Program Officer, Marine Fisheries
Advisory Committee, National Marine
Fisheries Service.
[FR Doc. 2021–20782 Filed 9–23–21; 8:45 am]
BILLING CODE 3510–22–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2021–0049]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,259,184;
Vernakalant Hydrochloride
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
[FR Doc. 2021–20764 Filed 9–23–21; 8:45 am]
BILLING CODE 3510–16–P
AGENCY:
DEPARTMENT OF COMMERCE
Patent and Trademark Office
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,259,184
(‘184 patent).
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On July 14, 2020, Correvio
International Sa`rl, the owner of record
of the ‘184 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
the ‘184 patent. The ‘184 patent claims
a method of using the product
vernakalant hydrochloride. The
application for interim patent term
extension indicates that New Drug
Application No. 22–034 for vernakalant
hydrochloride was submitted to the
Food and Drug Administration (FDA) on
December 19, 2006, and that the FDA’s
review thereof is ongoing.
Review of the interim patent term
extension application indicates that,
SUMMARY:
VerDate Sep<11>2014
16:50 Sep 23, 2021
Jkt 253001
[Docket No. PTO–P–2021–0050]
Grant of Interim Extension of the Term
of U.S. Patent No. 7,524,879;
Vernakalant Hydrochloride
a method of using the product
vernakalant hydrochloride. The
application for interim patent term
extension indicates that New Drug
Application No. 22–034 for vernakalant
hydrochloride was submitted to the
Food and Drug Administration (FDA) on
December 19, 2006, and that the FDA’s
review thereof is ongoing.
Review of the interim patent term
extension application indicates that,
except for permission to market or use
the product commercially, the ‘879
patent would be eligible for an
extension of the patent term under 35
U.S.C. 156. Because it appears the
approval phase of the regulatory review
period will continue beyond the
extended expiration date of the patent,
i.e., October 6, 2021, interim extension
of the ‘879 patent’s term under 35 U.S.C.
156(d)(5) is appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
7,5242,879 is granted for a period of one
year from the extended expiration date
of the ‘879 patent.
Robert Bahr,
Deputy Commissioner for Patents, United
States Patent and Trademark Office.
[FR Doc. 2021–20765 Filed 9–23–21; 8:45 am]
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
BILLING CODE 3510–16–P
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,524,879
(‘879 patent).
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
extended for no more than five interim
periods of up to one year each, if the
approval phase of the regulatory review
period is reasonably expected to extend
beyond the expiration date of the patent.
On July 14, 2020, Correvio
International Sa`rl, the owner of record
of the ‘879 patent, timely filed an
application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
the ‘879 patent. The ‘879 patent claims
[Docket No. PTO–P–2021–0048]
AGENCY:
SUMMARY:
PO 00000
Frm 00009
Fmt 4703
Sfmt 4703
DEPARTMENT OF COMMERCE
Patent and Trademark Office
Grant of Interim Extension of the Term
of U.S. Patent No. 7,057,053;
Vernakalant Hydrochloride
United States Patent and
Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term
extension.
AGENCY:
The United States Patent and
Trademark Office has issued an order
granting a one-year interim extension of
the term of U.S. Patent No. 7,057,053
(‘053 patent).
FOR FURTHER INFORMATION CONTACT: Ali
Salimi, Senior Legal Advisor, Office of
Patent Legal Administration, by
telephone at 571–272–0909 or by email
to ali.salimi@uspto.gov.
SUPPLEMENTARY INFORMATION: 35 U.S.C.
156 generally provides that the term of
a patent may be extended for a period
of up to five years, if the patent claims
a product, or a method of making or
using a product, that has been subject to
certain defined regulatory review. 35
U.S.C. 156(d)(5) generally provides that
the term of such a patent may be
SUMMARY:
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 86, Number 183 (Friday, September 24, 2021)]
[Notices]
[Page 53036]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-20764]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2021-0049]
Grant of Interim Extension of the Term of U.S. Patent No.
7,259,184; Vernakalant Hydrochloride
AGENCY: United States Patent and Trademark Office, Department of
Commerce.
ACTION: Notice of interim patent term extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued an
order granting a one-year interim extension of the term of U.S. Patent
No. 7,259,184 (`184 patent).
FOR FURTHER INFORMATION CONTACT: Ali Salimi, Senior Legal Advisor,
Office of Patent Legal Administration, by telephone at 571-272-0909 or
by email to [email protected].
SUPPLEMENTARY INFORMATION: 35 U.S.C. 156 generally provides that the
term of a patent may be extended for a period of up to five years, if
the patent claims a product, or a method of making or using a product,
that has been subject to certain defined regulatory review. 35 U.S.C.
156(d)(5) generally provides that the term of such a patent may be
extended for no more than five interim periods of up to one year each,
if the approval phase of the regulatory review period is reasonably
expected to extend beyond the expiration date of the patent.
On July 14, 2020, Correvio International S[agrave]rl, the owner of
record of the `184 patent, timely filed an application under 35 U.S.C.
156(d)(5) for an interim extension of the term of the `184 patent. The
`184 patent claims a method of using the product vernakalant
hydrochloride. The application for interim patent term extension
indicates that New Drug Application No. 22-034 for vernakalant
hydrochloride was submitted to the Food and Drug Administration (FDA)
on December 19, 2006, and that the FDA's review thereof is ongoing.
Review of the interim patent term extension application indicates
that, except for permission to market or use the product commercially,
the `184 patent would be eligible for an extension of the patent term
under 35 U.S.C. 156. Because it appears the approval phase of the
regulatory review period will continue beyond the extended expiration
date of the patent, i.e., October 6, 2021, interim extension of the
`184 patent's term under 35 U.S.C. 156(d)(5) is appropriate.
An interim extension under 35 U.S.C. 156(d)(5) of the term of U.S.
Patent No. 7,259,184 is granted for a period of one year from the
extended expiration date of the `184 patent.
Robert Bahr,
Deputy Commissioner for Patents, United States Patent and Trademark
Office.
[FR Doc. 2021-20764 Filed 9-23-21; 8:45 am]
BILLING CODE 3510-16-P
